Source: Pharmabiz

Eyestem: Eyestem to submit data for approval of phase 2a firstinhuman study to DCGI for Eyesight RPE for dry AMD

Eyestem will be submitting data for approval of phase 2a first─in─human study for its product named as Eyesight RPE to the Drugs Controller General of India (DCGI) for dry age─related macular degeneration

Read full article »

Eyestem's Competitors | Eyestem's News | Eyestem's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

Co-Founder & CEO

Jogin Desai

CEO Approval Rating

90/100

Eyestem is an India-based biotechnology company that develops and commercializes cell-based therapies for the treatment of dry age-related macular degeneration disorders.